We are excited to announce two new studies for Type 1 Diabetics. Both studies are under a year in length, and are seeking the benefits of new drugs to use in place of the existing FDA approved drug NovoLog.
The Gemelli X trial is designed for patients over the age of 18, male or female, who have been diagnosed and treating diabetes for a year or longer. We are seeking patients with an Hba1c of less than 10% and a body mass index under 35. This study will last a short 18 weeks, with approximately 8 office visits. All necessary insulin and monitoring is provided with the study. There is no cost to participate… in fact, we compensate you for each completed office visit!
The Mylan trial is similar to the Gemelli X. We are enrolling male and female patients, between 18 and 65 years of age, who have had a Type 1 Diabetes diagnosis that they’ve been managing for a minimum of 6 months. The patient will have an Hba1c between 6.5 and 10%, and a body mass index between 18.5 and 35. This trial is about double in length, at an estimated 35 weeks. As with most trials, we’ll provide all insulin and monitoring necessary to manage your health and progress. Again, there is no cost to you, but you are compensated for each office visit throughout the length of the trial.
At this time, we are scheduling enrollment appointments with patients that are interested in participating. In addition to the above criteria, patients need to be currently taking one of the following: Antus, Basaglar, or Tuejeo and NovoLog. If you believe you meet all of the above, we’d love to hear from you. To schedule an introductory meeting, you can call our office at (805) 658-8460 or send us an email at firstname.lastname@example.org.
Our well trained team is committed to your health and will gladly work with your current care team to update them on your health throughout the process.